2019 Future of Venous Leg Ulcers (Crural ulcer) R&D Pipeline Drugs and Companies- Analysis of Global Venous Leg Ulcers (Crural ulcer) Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

January 2019 | 60 pages | ID: 26B3BDCEB42EN
VPAResearch

Abstracts

The global demand for Venous Leg Ulcers (Crural ulcer) treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Venous Leg Ulcers (Crural ulcer) pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Venous Leg Ulcers (Crural ulcer) pipeline companies from advancing their products into Phase 3 or Phase 4.

Venous Leg Ulcers (Crural ulcer) Report Description

The H1 2019 pipeline review report on Venous Leg Ulcers (Crural ulcer) pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Venous Leg Ulcers (Crural ulcer) pipeline compounds.

The Venous Leg Ulcers (Crural ulcer) pipeline guide presents information on all active drugs currently being developed for Venous Leg Ulcers (Crural ulcer). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Venous Leg Ulcers (Crural ulcer) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Venous Leg Ulcers (Crural ulcer) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Venous Leg Ulcers (Crural ulcer) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Venous Leg Ulcers (Crural ulcer) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Venous Leg Ulcers (Crural ulcer) pipeline report includes

• An overview of Venous Leg Ulcers (Crural ulcer) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of pipeline compounds
• Company wise list of pipeline compounds
• Mechanism of Action wise pipeline compounds
• For each pipeline product, the following details are provided-
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Venous Leg Ulcers (Crural ulcer) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Venous Leg Ulcers (Crural ulcer) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into the market through in-depth strategic analysis review
• Know the list of companies participating in global Venous Leg Ulcers (Crural ulcer) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

3.1 Venous Leg Ulcers (Crural ulcer) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
3.4 Companies involved in Venous Leg Ulcers (Crural ulcer) pipeline, H1- 2019
3.5 Mechanism of Action wise Venous Leg Ulcers (Crural ulcer) Pipeline Candidates

4. AUREALIS PHARMA AG VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

4.1 Aurealis Pharma AG Business Profile
4.2 Aurealis Pharma AG Venous Leg Ulcers (Crural ulcer) Drug Details
  4.2.1 Drug Snapshot
    4.2.1.1 Originator
    4.2.1.2 Collaborator/Co-Developer
    4.2.1.3 Route of Administration
    4.2.1.4 Orphan Drug/Fast Track/Special Designation
    4.2.1.5 Area
    4.2.1.6 Type of Molecular Entity
4.3 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5. CARDIOVASCULAR BIOTHERAPEUTICS INC VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

5.1 CardioVascular BioTherapeutics Inc Business Profile
5.2 CardioVascular BioTherapeutics Inc Venous Leg Ulcers (Crural ulcer) Drug Details
  5.2.1 Drug Snapshot
    5.2.1.1 Originator
    5.2.1.2 Collaborator/Co-Developer
    5.2.1.3 Route of Administration
    5.2.1.4 Orphan Drug/Fast Track/Special Designation
    5.2.1.5 Area
    5.2.1.6 Type of Molecular Entity
5.3 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6. CYTOTOOLS AG VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

6.1 CytoTools AG Business Profile
6.2 CytoTools AG Venous Leg Ulcers (Crural ulcer) Drug Details
  6.2.1 Drug Snapshot
    6.2.1.1 Originator
    6.2.1.2 Collaborator/Co-Developer
    6.2.1.3 Route of Administration
    6.2.1.4 Orphan Drug/Fast Track/Special Designation
    6.2.1.5 Area
    6.2.1.6 Type of Molecular Entity
6.3 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7. DAVAL INTERNATIONAL LTD VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

7.1 Daval International Ltd Business Profile
7.2 Daval International Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
  7.2.1 Drug Snapshot
    7.2.1.1 Originator
    7.2.1.2 Collaborator/Co-Developer
    7.2.1.3 Route of Administration
    7.2.1.4 Orphan Drug/Fast Track/Special Designation
    7.2.1.5 Area
    7.2.1.6 Type of Molecular Entity
7.3 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8. FACTOR THERAPEUTICS LTD VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

8.1 Factor Therapeutics Ltd Business Profile
8.2 Factor Therapeutics Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
  8.2.1 Drug Snapshot
    8.2.1.1 Originator
    8.2.1.2 Collaborator/Co-Developer
    8.2.1.3 Route of Administration
    8.2.1.4 Orphan Drug/Fast Track/Special Designation
    8.2.1.5 Area
    8.2.1.6 Type of Molecular Entity
8.3 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9. FIRSTSTRING RESEARCH INC VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

9.1 FirstString Research Inc Business Profile
9.2 FirstString Research Inc Venous Leg Ulcers (Crural ulcer) Drug Details
  9.2.1 Drug Snapshot
    9.2.1.1 Originator
    9.2.1.2 Collaborator/Co-Developer
    9.2.1.3 Route of Administration
    9.2.1.4 Orphan Drug/Fast Track/Special Designation
    9.2.1.5 Area
    9.2.1.6 Type of Molecular Entity
9.3 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10. HYPO-STREAM LTD VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

10.1 Hypo-Stream Ltd Business Profile
10.2 Hypo-Stream Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
  10.2.1 Drug Snapshot
    10.2.1.1 Originator
    10.2.1.2 Collaborator/Co-Developer
    10.2.1.3 Route of Administration
    10.2.1.4 Orphan Drug/Fast Track/Special Designation
    10.2.1.5 Area
    10.2.1.6 Type of Molecular Entity
10.3 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. ILKOS THERAPEUTICS INC VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

11.1 Ilkos Therapeutics Inc Business Profile
11.2 Ilkos Therapeutics Inc Venous Leg Ulcers (Crural ulcer) Drug Details
  11.2.1 Drug Snapshot
    11.2.1.1 Originator
    11.2.1.2 Collaborator/Co-Developer
    11.2.1.3 Route of Administration
    11.2.1.4 Orphan Drug/Fast Track/Special Designation
    11.2.1.5 Area
    11.2.1.6 Type of Molecular Entity
11.3 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12. MALLINCKRODT PLC VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

12.1 MallInckrodt Plc Business Profile
12.2 MallInckrodt Plc Venous Leg Ulcers (Crural ulcer) Drug Details
  12.2.1 Drug Snapshot
    12.2.1.1 Originator
    12.2.1.2 Collaborator/Co-Developer
    12.2.1.3 Route of Administration
    12.2.1.4 Orphan Drug/Fast Track/Special Designation
    12.2.1.5 Area
    12.2.1.6 Type of Molecular Entity
12.3 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13. MEDIWOUND LTD VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

13.1 MediWound Ltd Business Profile
13.2 MediWound Ltd Venous Leg Ulcers (Crural ulcer) Drug Details
  13.2.1 Drug Snapshot
    13.2.1.1 Originator
    13.2.1.2 Collaborator/Co-Developer
    13.2.1.3 Route of Administration
    13.2.1.4 Orphan Drug/Fast Track/Special Designation
    13.2.1.5 Area
    13.2.1.6 Type of Molecular Entity
13.3 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14. PROMORE PHARMA AB VENOUS LEG ULCERS (CRURAL ULCER) PIPELINE DETAILS

14.1 Promore Pharma AB Business Profile
14.2 Promore Pharma AB Venous Leg Ulcers (Crural ulcer) Drug Details
  14.2.1 Drug Snapshot
    14.2.1.1 Originator
    14.2.1.2 Collaborator/Co-Developer
    14.2.1.3 Route of Administration
    14.2.1.4 Orphan Drug/Fast Track/Special Designation
    14.2.1.5 Area
    14.2.1.6 Type of Molecular Entity
14.3 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. LATEST VENOUS LEG ULCERS (CRURAL ULCER) DRUG PIPELINE DEVELOPMENTS, 2019

16. APPENDIX

16.1 About Us
16.2 Sources and Methodology
16.3 Contact Information